Back to results
US 10,016,470 B2Granted
Oncolytic adenoviruses for cancer treatment
AssigneeDnatrix, Inc.
InventorsRamon Alemany Bonastre, Juan Jose Rojas Exposito, Manel Maria Cascallo Piqueras
Life of this patent
Estimating the term…
Abstract
The invention relates to an oncolytic adenovirus for the treatment of cancer, containing a human DNA sequence isolating a promoter conferring selective expression on an adenoviral gene. Said adenovirus can also contain a sequence that optimizes the protein translation of an adenoviral gene regulated by a promoter conferring tumor selectivity. The invention is suitable for use in the treatment of cancer.
Claims12
An oncolytic adenovirus to treat cancer, the adenovirus comprising:
- an E1a gene, the E1a gene comprising a delta-24 mutation and operably linked to a tumor selective promoter that confers tumor selective expression of the E1a gene;
- and upstream of the promoter, a myotonic dystrophy insulator that comprises a CTCF binding site and insulates the promoter against transcriptional interference.
Dependencies are inferred from the claim text.